Payment overview · 2025
General Payments
$570.17
26 reported records · 14 companies
Healthcare provider profile · identity verified
Phillip Everett Dixon, MD
Allopathic & Osteopathic Physicians|Internal Medicine · REIDSVILLE, NC · NPI 1689296444
Verified facts
What the public records show
CMS Open Payments records show Phillip Everett Dixon, MD received $570.17 in general payments during 2025 across 26 reported records.
DePuy Synthes Sales Inc. accounted for 22.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| DePuy Synthes Sales Inc. | Unresolved — no canonical attribution shown | $129.68 | 22.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $95.44 | 16.7% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $50.72 | 8.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $50.41 | 8.8% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $50.11 | 8.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.06 | 5.8% | 2 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $26.55 | 4.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.38 | 4.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.16 | 3.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.02 | 3.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.68 | 3.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.87 | 3.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.12 | 2.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $13.97 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $570.17 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MONOVISC Normalized: monovisc |
Device | DePuy Synthes Sales Inc. | $129.68 | 2 | 2025 |
Source payment records
|
|||||
| ORTHOVISC Normalized: orthovisc |
Device | DePuy Synthes Sales Inc. | $129.68 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $61.19 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $50.72 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $50.11 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.25 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $31.80 | 2 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $26.55 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.38 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $21.02 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.04 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $13.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 82 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 93 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 117 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
82 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
91 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
93 | 16 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
117 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 383 | 134 |
| Amlodipine Besylate | Amlodipine Besylate | 326 | 94 |
| Gabapentin | Gabapentin | 217 | 57 |
| Lisinopril | Lisinopril | 183 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 166 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 165 | 54 |
| Ozempic | Semaglutide | 117 | 28 |
| Omeprazole | Omeprazole | 108 | 31 |
| Alprazolam | Alprazolam | 104 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 102 | 25 |
| Furosemide | Furosemide | 95 | 27 |
| Levothyroxine Sodium | Levothyroxine Sodium | 95 | 29 |
| Mounjaro | Tirzepatide | 93 | 16 |
| Jardiance | Empagliflozin | 91 | 26 |
| Carvedilol | Carvedilol | 88 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 41 |
| Metformin Hcl | Metformin Hcl | 86 | 26 |
| Farxiga | Dapagliflozin Propanediol | 82 | 18 |
| Ezetimibe | Ezetimibe | 81 | 26 |
| Losartan Potassium | Losartan Potassium | 78 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 71 | 19 |
| Trazodone Hcl | Trazodone Hcl | 71 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 70 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 14 |
| Chlorthalidone | Chlorthalidone | 65 | 19 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 65 | 27 |
| Metformin Hcl Er | Metformin Hcl | 65 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 15 |
| Allopurinol | Allopurinol | 57 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 14 |
| Potassium Chloride | Potassium Chloride | 52 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | suppressed |
| Lorazepam | Lorazepam | 50 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | suppressed |
| Simvastatin | Simvastatin | 48 | 15 |
| Spironolactone | Spironolactone | 48 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 47 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 44 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | 16 |
| Prednisone | Prednisone | 41 | 28 |
| Eliquis | Apixaban | 39 | suppressed |
| Meloxicam | Meloxicam | 39 | 15 |
| Montelukast Sodium | Montelukast Sodium | 39 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 13 |
| Labetalol Hcl | Labetalol Hcl | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 33 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 14 |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 13 |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 11 |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $570.17 · 26 records | DePuy Synthes Sales Inc. | AIRSUPRA, APRETUDE, CAPLYTA, Cologuard Collection Kit, EVENITY, FARXIGA, Kerendia, LEQVIO, MONOVISC, MOUNJARO, ORTHOVISC, Ozempic, QULIPTA, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error